Moderna announced positive results from its late-stage RSV vaccine trial in older adults.
Moderna's experimental respiratory syncytial virus vaccine was about 84% effective at protecting older adults from lower respiratory tract disease in a late-stage trial, the drugmaker announced Tuesday .
RSV most often causes mild, cold-like illnesses, but it can cause severe disease in infants, young children with certain medical conditions, and adults ages 65 and older, especially those with weakened immune systems or chronic heart or lung disease, according to the Centers for Disease Control and Prevention . There is no approved vaccine to prevent RSV, although several pharmaceutical companies are in the midst of late-stage trials testing vaccines in these high-risk groups.
All of the cases involved at least two symptoms of lower respiratory tract disease, such as cough and fever, and of these, 55 occurred in the placebo group and nine occurred in the vaccinated group. 20 cases involved three or more symptoms; 17 cases were in the placebo group, and three were in the vaccinated group.—12 microscopic discoveries that went 'viral' in 2022Based on these numbers, the vaccine was 83.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says RSV vaccine is 84% effective at preventing disease in older adultsRSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the CDC.
Read more »
Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsModerna Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus (RSV) was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Read more »
Moderna says its RSV vaccine for older adults is 84% effective at preventing serious illnessModerna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023.
Read more »
Moderna Reports RSV Vaccine Cuts Risk of Respiratory Diseases in Older AdultsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »
Moderna’s RSV Shot Prevents Most Cases in Older PeopleModerna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first...
Read more »
Moderna’s RSV Vaccine Reduces Risk of Respiratory Diseases, Study FindsAn RSV vaccine that Moderna is developing significantly reduced the risk of respiratory diseases in a key study, the company said
Read more »